CA12449/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1992	1
1996	1
1997	1
2001	3
2002	2
2003	1
2004	10
2005	5
2006	7
2007	2
2008	4
2009	5
2010	1
2011	1
2012	1
2013	1
2025	0

1

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP; Cancer Leukemia Group B. Bartlett NL, et al. Ann Oncol. 2007 Jun;18(6):1071-9. doi: 10.1093/annonc/mdm090. Epub 2007 Apr 10. Ann Oncol. 2007. PMID: 17426059 Free article. Clinical Trial.

2

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.

Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Rizzieri DA, et al. Cancer. 2004 Apr 1;100(7):1438-48. doi: 10.1002/cncr.20143. Cancer. 2004. PMID: 15042678 Free article. Clinical Trial.

3

Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.

Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Modeas C, Green MR. Strauss GM, et al. J Clin Oncol. 1992 Aug;10(8):1237-44. doi: 10.1200/JCO.1992.10.8.1237. J Clin Oncol. 1992. PMID: 1321893 Clinical Trial.

4

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L; Cancer and Leukemia Group B. Muss HB, et al. JAMA. 2005 Mar 2;293(9):1073-81. doi: 10.1001/jama.293.9.1073. JAMA. 2005. PMID: 15741529

5

Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804.

Alfano CM, Day JM, Katz ML, Herndon JE 2nd, Bittoni MA, Oliveri JM, Donohue K, Paskett ED. Alfano CM, et al. Psychooncology. 2009 Feb;18(2):128-33. doi: 10.1002/pon.1378. Psychooncology. 2009. PMID: 18536022 Free PMC article.

6

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.

Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease RF Jr, Weeks JC. Kilbridge KL, et al. J Clin Oncol. 2002 Mar 1;20(5):1311-8. doi: 10.1200/JCO.2002.20.5.1311. J Clin Oncol. 2002. PMID: 11870174 Clinical Trial.

7

Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.

Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG; Cancer and Leukemia Group B. Roberts JD, et al. J Immunother. 2006 Jan-Feb;29(1):95-101. doi: 10.1097/01.cji.0000195295.74104.ad. J Immunother. 2006. PMID: 16365605 Clinical Trial.

8

Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress.

Greenberg DB, Kornblith AB, Herndon JE, Zuckerman E, Schiffer CA, Weiss RB, Mayer RJ, Wolchok SM, Holland JC. Greenberg DB, et al. Cancer. 1997 Nov 15;80(10):1936-44. doi: 10.1002/(sici)1097-0142(19971115)80:10<1936::aid-cncr10>3.0.co;2-z. Cancer. 1997. PMID: 9366296

9

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS; Alliance for Clinical Trials in Oncology. Ogino S, et al. J Natl Cancer Inst. 2013 Dec 4;105(23):1789-98. doi: 10.1093/jnci/djt298. Epub 2013 Nov 14. J Natl Cancer Inst. 2013. PMID: 24231454 Free PMC article. Clinical Trial.

10

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Blanke CD, et al. J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452. J Clin Oncol. 2008. PMID: 18235122 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year